In March, the U.S. Food and Drug Administration approved Rejoyn, the first digital therapeutic to treat major depressive disorder. The app opens the door to a new class of therapies that could dramatically increase access to treatment. Six months later, the FDA approved the first new drug for schizophrenia in 30 years, Cobenfy. It targets a different brain chemical system than previous treatments. And psychedelics found a first when the FDA reviewed a request to approve MDMA for the treatment of posttraumatic stress disorder. Though this bid ultimately failed—the agency wanted more research—the FDA remains open to this group of drugs as a promising new approach for certain mental health conditions.